L-Tryptophan-Associated Eosinophilia-Myalgia Syndrome: Clinical and Pathological Features of an Evolving New Disease and Current Concepts of Etiology

Centers for Disease Control. Eosinophilia-myalgia syndrome: New Mexico. MMWR 1989 38: 765–767.

Centers for Disease Control. Eosinophilia-myalgia syndrome and L-tryptophan containing products in New Mexico, Minnesota, Oregon and New York. MMWR 1989;38: 785–788.

Centers for Disease Control. Clinical spectrum of eosinophilia-myalgia syndrome—California. MMWR 1989;39: 89–91.

Centers for Disease Control. Update: eosinophilia-myalgia syndrome associated with the ingestion of L-tryptophan containing products—United States through August 24, 1990. MMWR 1990;39: 587–591.

Hertzman PA Blevins WL Mayer J Association of the eosinophilia-myalgia syndrome with the ingestion of Tryptophan. N Engl J Med 1990;322: 869–874.

Steiber T. Three New Mexico women contract unusual syndrome. Albuquerque J November 7, 1989.

Eidson M Philen R Sewell CM L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990;375: 645–648.

Expanded recall for L-tryptophan. FDA Drug Bulletin 1990;20: 2–3.

Eidson M. Tryptophan. JAMA 1990;264:970.

Swygert L Maes EF Sewell LE Eosinophilia-myalgia syndrome: results of national surveillance. JAMA 1990; 264:1698–1703.

Kamb ML Murphy JJ Jones JL Eosinophilia-myalgia syndrome in L-tryptophan exposed patients. JAMA 1992;267: 77–72.

Hedberg K Urbach D Slutsker L Eosinophilia myalgia syndrome: natural history in a population-based cohort. Arch Intern Med 1992;152: 1889–1892.

Travis DW Kalafer ME Robin HS Hypersensitivity pneumonitis and pulmonary vasculitis with eosinophilia in a patient taking L-tryptophan preparation. Ann Intern Med 1990;112: 301–303.

Flannery MT Wallach PM Espinosa LR A case of eosinophilia-myalgia syndrome associated with use of an L-tryptophan product. Ann Intern Med 1990;112: 300–301.

Varga J Peltonen J Uitto J Jimenez SA Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues. Ann Intern Med 1990;112: 344–352.

Silver RS Heyes MP Maize JC Scleroderma, fasciitis and eosinophilia associated with the ingestion of Tryptophan. N Engl J Med 1990;322: 874–881.

Martin RW Duffy J Engel AE The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Ann Intern Med 1990;113: 124–134.

Clauw JD Nashel DJ Umhau A Katz P. Tryptophan-associated eosinophilic connective tissue disease. A new clinical entity? JAMA 1990;263: 1502–1506.

Kaufman L Seidman RJ Gruber BL. L-tryptophan associated eosinophilic perimyositis, neuritis and fasciitis. A clinico-pathological and laboratory study of 25 patients. Medicine 1990;69: 187–199.

Roubenoff R Cote T Watson R Eosinophilia-myalgia syndrome due to L-tryptophan ingestion: report of four cases and review of the Maryland experience. Arthritis Rheum 1990;33: 930–939.

Bulpitt KJ Verity AM Clements PJ Paulus HE. Association of L-tryptophan and an illness resembling eosinophilic fasciitis: clinical and histopathological findings in four patients with eosinophilia-myalgia syndrome. Arthritis Rheum 1990;33: 918–930.

Glickstein SL Gertner E Smith SA Eosinophilia-myalgia syndrome associated with L-tryptophan use. J Rheumatol 1990;17: 1534–1543.

Varga J Heiman-Patterson TD Emery DL Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum 1990;19: 313–328.

Amor B Rajzbaum G Poirandeau S Eosinophilia-myalgia linked with L-tryptophan. Lancet 1990;335:420.

Connolly SM Quimby SR Griffing WL Scleroderma and L-tryptophan: a possible explanation of the eosinophilia-myalgia syndrome. J Am Acad Dermatol 1990;23: 451–457.

Kaufman LD Seidman RJ Phillips ME Gruber BL. Cutaneous manifestations of the L-tryptophan associated eosinophilia-myalgia syndrome: a spectrum of sclerodermatous skin disease. J Am Acad Dermatol 1990;23: 1063–1069.

Feldman SR Silver RM Maize JC. A histopathologic comparison of Shulman's syndrome and the fasciitis associated with the eosinophilia-myalgia syndrome. J Am Acad Dermatol 1992;26: 95–100.

Rodnan GP DiBartolomeo AG Medsger TA Jr Barnes EL. Eosinophilic fasciitis: report of 7 cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 1975;18: 422–423.

Moutsopoulos HM Webber BL Fostiropoulos G Diffuse fasciitis with eosinophilia: a clinicopathological study. AmJ Med 1980;68: 701–709.

Dubin DB Kwan TM Case DC. Cutaneous mucinosis in a patient with eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Arch Dermatol 1990;126: 1517–1518.

Farmer KL Hebert A Rapini RP Dermal mucinosis in the eosinophilia-myalgia syndrome. Arch Dermatol 1990;126: 1518–1520.

Mainetti C Masouyel I Saurat J-M. Pseudoxanthoma elasticum-like lesions in the l-tryptophan induced eosinophilia-myalgia syndrome. J Am Acad Dermatol 1991;24: 657–658.

Dicker RM James N Curka BA. The eosinophilia-myalgia syndrome with neuritis associated with L-tryptophan use. Ann Intern Med 1990;112: 957–958.

Kaufman LD Fran AF Seidman RJ Eosinophilic neuritis, perimyositis and vasculitis associated with ingestion of L-tryptophan. J Rheumatol 1990;17: 795–800.

Smith BE Dyck PJ. Peripheral neuropathy in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Neurology 1990;40: 1035–1040.

Heiman-Patterson TD Bird SJ Parry GJ Peripheral neuropathy associated with the eosinophilia-myalgia syndrome. Ann Neurol 1990;28: 522–528.

Heiman-Patterson T Varga J. Neurologic complications of the hypereosinophilic syndromes. In: Goetz CG Tanner CM Aminoff MJ , eds. Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishers, 1993 (in press).

Ivey M Eichemham MN Glasberg MR Hizy RC. Hypercapnic respiratory failure due to L-tryptophan-induced eosinophilic polymyositis. Chest 1991;99: 756–757.

Seidman RJ Kaufman LD Sokoloff L The neuromuscular pathology of the eosinophilia-myalgia syndrome. J Neuropathol Exp Neurol 1991;50: 49–62.

Tolander LM Bamford CR Toskimo MT Neurological complications of the tryptophan-associated eosinophilia-myalgia syndrome. Arch Neurol 1991;48: 436–438.

Krupp LB Masur DM Kaufman LD. Neurocognitive dysfunction in the eosinophilia-myalgia syndrome. Neurology 1993 (in press).

Verity AM Bulpitt KJ Paulus ME. Neuromuscular manifestations of L-tryptophan-associated eosinophilia-myalgia syndrome: a histomorphometric analysis of 14 patients. Hum Pathol 1991;22: 3–11.

Talpos DC Scartsen SA Silverman J Perimyositis with perineuritis and myofiber type grouping in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Am J Surg Pathol 1991;15: 222–226.

Williamson MR Eidson M Rosenberg RD Williamson SL. Eosinophilia-myalgia syndrome: findings on chest radiographs in 18 patients. Radiology 1991;180: 849–852.

Campagna AC Blanc PD Criswell LA Pulmonary manifestations of the eosiophilia-myalgia syndrome associated with tryptophan ingestion. Chest 1992;101: 1274–1281.

Strumpf JI Drucker RD Anders KH Acute eosinophilic pulmonary disease associated with the ingestion of L-trypto-phan-containing products. Chest 1991;99: 8–13.

Tazelaar HD Myers JL Drage CW Pulmonary disease associated with L-tryptophan induced eosinophilia-myalgia syndrome. Chest 1990;97: 1032–1036.

Yakovlevitch M Seigel M Hoch DH Rutlen DL. Pulmonary hypertension in a patient in tryptophan-induced eosinophilia-myalgia syndrome. AmJ Med 1991;90: 272–273.

DeSchryver-Kecskemeti K Bennert KW Cooper GS Yang P. Gastrointestinal-involvement in L-tryptophan associated eosinophilia-myalgia syndrome. Dig Dis Sci 1992;37: 697–701.

Hertzman PA Maddoux GL Stenberg EM Heyes MP Gleich GJ. Repeated coronary artery spasm in a young woman with eosinophilia-myalgia syndrome. JAMA 1992;267: 2932–2934.

James TN Kamb ML Sandberg GA Post-mortem studies of the heart in three fatal cases of the eosinophilia-myalgia syndrome. Ann Intern Med 1991;115: 102–110.

Freundlich B Werth VP Rook AH L-tryptophan ingestion is associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med 1990;112: 758–762.

Chiba S Miyagawa K Tanaka T Tryptophan-associated eosinophilia-myalgia syndrome and pancreatitis. Lancet 1990;336:121.

Jaffe PJ Gertner E Miller W. Absent neutrophil alkaline phosphatase in the eosinophilia-myalgia syndrome associated with L-tryptophan use. Am J Hematol 1991;36: 280–281.

Criswell LA Sack KA Tryptophan-induced eosinophilia-myalgia syndrome. West J Med 1990;153: 269–274.

Duffy J. Lessons of eosinophilia-myalgia syndrome. Hosp Pract 1992;27: 65–90.

Medsger TA Jr. Progressive systemic sclerosis: skeletal muscle involvement. Clin Rheum Dis 1979;5: 103–113.

Kilbourne E Rigau-Perez JG Heath CW Clinical epidemiology of the toxic oil syndrome: manifestations of a new illness. N Engl J Med 1983;309: 1408–1414.

Varga J Maul G Jimenez SA Autoantibodies to lamin C in the L-tryptophan-associated eosinophilia-myalgia syndrome. Arthritis Rheum 1992;35: 106–109.

Kaufman L Gruber B Gregersen P. Clinical follow-up and immunogenetic studies of 35 patients with the eosinophilia myalgia syndrome. Lancet 1991 337: 1071–1074.

Kim SM Park CH Intenso CM Gallium uptake in tryptophan-related pulmonary disease. J Nucl Med 1991; 32:328–329.

Rao MG Chauhan D Mengel CE. Gallium uptake in eosinophilia-myalgia syndrome. J Nucl Med 1991 32:2026.

Caston JC Roufs JB Fargarty CM Treatment of refractory eosinophilia-myalgia syndrome associated with the ingestion of L-tryptophan containing products. Adv Therapy 1990;7: 206–228.

Culpepper RC Williams RG Mease PJ Natural history of the eosinophilia-myalgia syndrome. An Intern Med 1991; 115:437–442.

Shulman LE. The eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan. Arthritis Rheum 1990 33: 913–918.

Weller PF. The immunobiology of eosinophils. N Engl J Med 1991 324: 1110–1119.

Durack D Sumi S Klebanoff S. Neurotoxicity of human eosinophils. Proc Nati Acad Sei USA 1979;76: 1443–1447.

Gleich GJ Frigas E Loegering DA Cytotoxic properties of the eosinophil major protein. J Immunol 1979;123: 2925–2927.

Rohrbach MS Wheatley CL Slifman NR Activation of platelets by eosinophil granule proteins. J Exp Med 1990;172: 1271–1274.

Wingqvist I Oloffson T Olsson I Altered density, metabolism and surface receptors of eosinophils in eosinophilia. J Immunol 1982;47: 531–539.

Owen WF Rothenberg ME Silberstein DS Interleukin-5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. J Exp Med 1987;166: 129–141.

Rothenberg ME Owen WF Silberstein DS Human eosinophils have prolonged survival, enhanced functional properties and become hypodense when exposed to human interleukin 3. J Clin Invest 1988;81: 1986–1992.

Fauci AS Harley JB Roberts WC The idiopathic hypereosinophilic syndrome. Ann Intern Med 1982;97: 78–92.

Owen WF Petersen J Sheff DM Hypodense eosinophils and interleukin-5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc Natl Acad Sci USA 1990;87: 8647–8651.

Toxic-Epidemic Study Group. Toxic epidemic syndrome, Spain, 1981. Lancet 1982;2: 697–702.

Kilbourne EM Bernert JT Posada M Chemical correlates of pathogenecity of oils related to the toxic oil syndrome in Spain. Am J Epidemiol 1988;127: 1210–1227.

Kilbourne EM Posada M Borda IA TOS: a current chemical and epidemiologic summary, including comparisons with the EMS. J Am Coll Cardiol 1991;18: 711–717.

Ten RM Kephart GM Posada M Participation of eosinophils in the toxic oil syndrome. Clin Exp Immunol 1990;82: 313–327.

Schneider-Helmert D Spinweber CL. Evaluation of L-tryptophan for the treatment of insomnia: a review. Psychophar-macology 1986;89: 1–7.

Young SN Teff KL. Tryptophan availability, 5HT synthesis and 5HT function. Prog Neuro-Psychopharmacol Biol Psychol 1989;13: 373–379.

Belongia EA Hedberg VW Gleich GJ An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990;323: 357–366.

Slutsker L Hoesly FC Miller L Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 1990;264: 213–217.

Centers for Disease Control. Analysis of L-tryptophan for the etiology of eosinophilia-myalgia syndrome. MMWR 1990;39: 589–591.

Mayeno A Lin F Foote CS Characterization of “peak E,” a novel amino acid associated with the eosinophiliamyalgia syndrome. Science 1990;250: 1707–1708.

Barrhart ER Maggio BL Alexander LR Bacitracin-associated peptides and contaminated L-tryptophan. Lancet 1990;336:742.

Swinbanks D Anderson C. Search for contaminant in eosinophilia-myalgia syndrome goes slowly. Nature 1992;358:96.

Mayeno AN Belongia EA Liu F 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome? Mayo Clin Proc 1992;67: 1134–1139.

Strongwater SL Woda BA Yood RA Eosinophiliamyalgia syndrome associated with L-tryptophan ingestion. Arch Intern Med 1990;150: 2178–2186.

Peltonen J Varga J Sollberg S Elevated expression of the genes for transforming growth factor-®1 and Type VI collagen in diffuse fasciitis associated with the eosinophilia-myalgia syndrome. J Invest Dermatol 1990;96: 20–25.

Varga J Li L Jimenez SA Elevated type I collagen production by fibroblasts derived from eosinophilia-myalgia syndrome skin. J Rheumatol 1993 (in press).

Roberts AB Sporn MB Assoian RK Transforming growth factor-type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen synthesis in vitro. Proc Nati Acad Sci USA 1986;83: 4167–4171.

Varga J Rosenbloom J Jimenez SA Transforming growth factor ®(TGF®) causes a persistent increase in steady-state amount of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem 1987;247: 597–604.

Gruschwitz M Muller PU Sepp N Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94: 197–203.

Connor TB Roberts AB Sporn MB Correlation of fibrosis and transforming growth factor-® type II levels in the eye. J Clin Invest 1989;83: 1661–1666.

Peltonen J Kähäri L Jaakkola S Evaluation of transforming growth factor ® and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990;94: 365–371.

Medsger TA Jr. Tryptophan-induced eosinophilia-myalgia syndrome (editorial). N Engl J Med 1990 322: 926–928.

Shulman LE. Diffuse fasciitis with eosinophilia—a new syndrome? Trans Assoc Am Physicians 1975;88: 70–86.

Canoso JJ. Case records of the Massachusetts General Hospital (Case 4-1990). N Engl J Med 1990 322: 252–260.

Gordon ML Lebwohl MG Phelps RG Fleischmajer R. Eosinophilic fasciitis associated with tryptophan ingestion. Arch Dermatol 1991;127: 217–220.

Varga J Griffin R Newman J Jimenez SA Eosinophilic fasciitis is not associated with L-tryptophan ingestion and is distinguishable from eosinophilia-myalgia syndrome. J Rheumatol 1991;18: 259–263.

Jimenez SA Varga J Is eosinophilic fasciitis caused by L-tryptophan? Curr Med Lit Rheum 1991;10: 35–40.